Ginkgo Bioworks (NYSE: DNA) reported Q2 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $80.6 million versus the consensus estimate of $71.5 million.

GUIDANCE:

Ginkgo Bioworks sees FY2023 revenue of $245-260 million, versus the consensus of $292.8 million.

For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.